A Phase 1/2 Randomized Study to Evaluate the Safety Tolerability Immunogenicity And Immunopersistence of a Clostridioides Difficile Vaccine Administered in a 2-Dose Regimen with Novel Adjuvants in Healthy Adults

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Clostridium Difficile
  • Age: Between 65 Year(s) - 110 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Healthy adult
    2. 65 years of age or older
    3. Agree to comply with all study requirements

You may not be eligible for this study if the following are true:

    1. History of severe reaction associated with a vaccine
    2. Immunocompromised individuals with known or suspected Immunodeficiency
    3. Previously received an investigational Clostridioides difficile (C. diff) vaccine or C. diff monoclonal antibody therapy
    4. Have had a confirmed episode of C. diff infection

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.